ACLS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sahin, M.
Right arrow Articles by Yilmaz, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sahin, M.
Right arrow Articles by Yilmaz, N.
Annals of Clinical & Laboratory Science 36:449-454 (2006)
© 2006 Association of Clinical Scientists

Asymmetric Dimethylarginine and Nitric Oxide Levels as Signs of Endothelial Dysfunction in Behcet’s Disease

Mehmet Sahin1, Cagatay Arslan1, Mustafa Naziroglu2, S. Ercan Tunc1, Mustafa Demirci3, Recep Sutcu4 and Nigar Yilmaz4
1 Departments of Internal Medicine, 2 Biophysics, 3 Microbiology and Clinical Microbiology, and 4 Biochemistry, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey

Address correspondence to Professor Mustafa Naziroglu, Department of Biophysics, Medical Faculty, Suleyman Demirel University, Postakutusu 68 Cunur, TR-32260 Isparta, Turkey; tel 90 246 211 3310; fax 90 246 237 1165; e-mail mnaziroglu{at}med.sdu.edu.tr.

Behcet’s disease (BD) has been known for many years, yet the etiology of the systemic vasculitis remains unknown. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthase. ADMA is involved in endothelial dysfunction in various vascular diseases and its level in BD is unclear. This study was performed to evaluate the relationship between ADMA and NO levels in plasma of patients with BD. There were 3 groups of 30 subjects: (a) controls, (b) BD patients with mucocutaneous involvement, and (c) BD patients with vascular involvement. Plasma NO levels were assayed by spectrophotometry and plasma ADMA levels were assayed by an ELISA test. Plasma ADMA levels were higher in both groups of BD patients than in the controls; the ADMA levels were higher in the BD patients with vascular involvement than in the mucocutaneous group. Plasma NO levels were lower in both groups of BD patients than in controls; plasma NO levels were lower in the BD patients with vascular involvement than in mucocutaneous group. In the combined groups of 60 BD patients, there was significant inverse correlation between the plasma concentrations of ADMA and NO (r = –0.570, p <0.001). Plasma lipid profiles did not differ significantly between the BD patients and the controls. These results are evidence for increased plasma ADMA levels and decreased plasma NO levels as risk factors for cardiovascular events in BD patients. Inhibition of NO synthesis by ADMA may contribute to vascular involvement in BD.

Keywords: nitric oxide, Behcet’s disease, asymmetric dimethylarginine (ADMA), vasculitis, endothelial inflammation

Abbreviations: ADMA, asymmetric dimethylarginine; BD, Behcet’s disease; CRP, C reactive protein; DDAH, dimethylaminohydrolase; ESR, erythrocyte sedimentation rate; NO, nitric oxide; NOS, nitric oxide synthase






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Association of Clinical Scientists.